Contents lists available at ScienceDirect Autoimmunity Reviews
Omer Gendelman, Howard Amital, Nicola Luigi Bragazzi, Abdulla Watad, Gabriel Chodick, A B S T R A C T
Background: Some disease-modifying agents commonly used to treat patients with rheumatic diseases/autoimmune disorders, such as hydroxychloroquine and colchicine, are under investigation as potential therapies for the "coronavirus disease 2019" (COVID-19). However, the role of such agents as prophylactic tools is still not clear. Methods: This is a retrospective study based on a large healthcare computerized database including all patients that were screened for the "Severe Acute Respiratory Syndrome Coronavirus type 2" (SARS-CoV-2) in the study period from February 23rd 2020 to March 31st 2020. A comparison was conducted between subjects tested positive for SARS-CoV-2 and those found negative in terms of rate of administration of hydroxychloroquine/ colchicine therapy. Results: An overall sample of 14,520 subjects were screened for SARS-CoV-2 infection and 1317 resulted positive. No significant difference was found in terms of rates of usage of hydroxychloroquine or colchicine between those who were found positive for SARS-CoV-2 and those who were found negative (0.23% versus 0.25% for hydroxychloroquine, and 0.53% versus 0.48% for colchicine, respectively). Conclusion: These findings raise doubts regarding the protective role of these medications in the battle against SARS-CoV-2 infection.
References
Appel, Kaidar-Person, Lawrence, Ben-Ayun, Katzman et al., The coronavirus pandemic in Israel: implications for radiation oncology departments, IMAJ
Covid, Team, Severe outcomes among patients with coronavirus disease 2019 (COVID-19)-United States, February 12, MMWR Morb Mortal Wkly Rep
Deftereos, Siasos, Giannopoulos, Vrachatis, Angelidis et al., The GReek study in the effects of colchicine in COvid-19 complications prevention (GRECCO-19 study): rationale and study design, Hellenic J Cardiol,
doi:10.1016/j.hjc.2020.03.002Garg, Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019-COVID-NET, 14 states, march, MMWR Morb Mortal Wkly Rep
Grossman, Farberov, Feld, Livneh, Ben-Zvi, Efficacy and safety of longterm treatment with intravenous colchicine for familial Mediterranean fever (FMF) refractory to oral colchicine, Rheumatol Int
Guan, Ni, Hu, Liang, Ou et al., Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med,
doi:10.1056/NEJMoa2002032Infantino, Damiani, Gobbi, Grossi, Lari et al., Serological assays for SARS-CoV-2 infectious disease: benefits, limitations and perspectives, IMAJ
Kanduc, Shoenfeld, On the molecular determinants the SARS-CoV-2 attack, Clin Immunol
Kerpel, Nissan, Klug, Amit, Konen et al., Imaging findings in four COVID-19 patients, IMAJ
Kimball, Hatfield, Arons, James, Taylor et al., Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019-United States
Lancet, The gendered dimensions of COVID-19, Lancet
Leung, Hui, Kraus, Colchicine -update on mechanisms of action and therapeutic uses, Semin Arthritis Rheum
Li, Yang, Zhao, Zhi, Wang et al., Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China, Clin Res Cardiol,
doi:10.1007/s00392-020-01626-9Oestergaard, Schmiegelow, Bruun, Skov, Petersen et al., The associations between socioeconomic status and risk of Staphylococcus aureus bacteremia and subsequent endocarditis -a Danish nationwide cohort study, BMC Infect Dis
Pascart, Richette, Colchicine in gout: an update, Curr Pharm Des
Petrilli, Jones, Yang, Rajagopalan, Donnell et al., Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in
Rodriguez-Morales, Cardona-Ospina, Gutiérrez-Ocampo, Villamizar-Peña, Holguin-Rivera et al., Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis, Travel Med Infect Dis
Rubin, Baden, Morrissey SAudio Interview: Loosening Covid-19 Restrictions, N Engl J Med
Ruiz-Irastorza, Olivares, Ruiz-Arruza, Martinez-Berriotxoa, Egurbide et al., Predictors of major infections in systemic lupus erythematosus, Arthritis Res Ther
Sanders, Monogue, Jodlowski, Cutrell, Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review, JAMA,
doi:10.1001/jama.2020.6019Savarino, Trani, Donatelli, Cauda, Cassone, New insights into the antiviral effects of chloroquine, Lancet Infect Dis
Shoenfeld, Corona, COVID-19) time musings: our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning, Autoimmun Rev,
doi:10.1016/j.autrev.2020.102538Sun, He, Wang, Lai, Ji et al., COVID-19: epidemiology, evolution, and cross-disciplinary perspectives, Trends Mol Med
Surveillances, The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)-China, China CDC Weekly
Tang, Godfrey, Stawell, Nikpour, Hydroxychloroquine in lupus: emerging evidence supporting multiple beneficial effects, Intern Med J
Wu, Mcgoogan, Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention, JAMA,
doi:10.1001/jama.2020.2648Yang, Zheng, Gou, Pu, Chen et al., Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and metaanalysis, Int J Infect Dis,
doi:10.1016/j.ijid.2020.03.017
